Article

Expert: Efficacy of COVID-19 Boosters Against Variants of Concern Is Unknown

Amesh Adalja, MD, FIDSA, FACP, FACEP, said that the efficacy of COVID-19 booster vaccines against variants of concern is still relatively unknown, although administering the third shots does increase antibodies as expected.

In an interview with Pharmacy Times, Amesh Adalja, MD, FIDSA, FACP, FACEP, said that the efficacy of COVID-19 booster vaccines against variants of concern is still relatively unknown, although administering the third shots does increase antibodies as expected. Adalja said that leaked reports suggest the Biden administration is planning to recommend booster vaccines for adults 8 months after their second dose, and that recommendation could come in the next few days.

Although booster shots could be a necessary step forward in the pandemic, Adalja said he believes it is more important to vaccinate those who are still unvaccinated, rather than focusing all attention on boosting the immune systems of vaccinated individuals. He noted that the vast majority of hospitalized patients with severe COVID-19 are unvaccinated, demonstrating that even just 2 doses of the vaccines are proving effective.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: Dr_Microbe | stock.adobe.com